Literature DB >> 14722095

Thiol modification of cysteine 327 in the eighth transmembrane domain of the light subunit xCT of the heteromeric cystine/glutamate antiporter suggests close proximity to the substrate binding site/permeation pathway.

Maite Jiménez-Vidal1, Emma Gasol, Antonio Zorzano, Virginia Nunes, Manuel Palacín, Josep Chillarón.   

Abstract

We measured sensitivity to thiol modification of the heteromeric glutamate/cystine transporter 4F2hc-xCT expressed in Xenopus oocytes. p-Chloromercuribenzoate (pCMB) and p-chloromercuribenzenesulfonate (pCMBS) rapidly blocked transport activity. Cys(327), located in the middle of the eighth transmembrane domain of the light subunit (xCT), was found to be the main target of inactivation. Cysteine, an impermeant reducing reagent, reversed pCMB and pCMBS effects only when applied from the extracellular medium. l-Glutamate and l-cystine, but not l-arginine, protected from the inactivation with an IC(50) similar to the K(m). Protection was not temperature-dependent, suggesting that it did not depend on large substrate-induced conformational changes. Mutation of Cys(327) to Ala and Ser slightly modified the K(m) and a C327L mutant abolished transport function without compromising transporter expression at the plasma membrane. The results indicate that Cys(327) is a functionally important residue accessible to the aqueous extracellular environment and is structurally linked to the permeation pathway and/or the substrate binding site.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722095     DOI: 10.1074/jbc.M309866200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  In silico characterization of residues essential for substrate binding of human cystine transporter, xCT.

Authors:  Monika Sharma; C R Anirudh
Journal:  J Mol Model       Date:  2019-11-09       Impact factor: 1.810

2.  System xc⁻ cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS.

Authors:  Richard J Bridges; Nicholas R Natale; Sarjubhai A Patel
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

3.  Role of transmembrane domain 8 in substrate selectivity and translocation of SteT, a member of the L-amino acid transporter (LAT) family.

Authors:  Paola Bartoccioni; César Del Rio; Merce Ratera; Lukasz Kowalczyk; Jocelyn M Baldwin; Antonio Zorzano; Matthias Quick; Stephen A Baldwin; José Luis Vázquez-Ibar; Manuel Palacín
Journal:  J Biol Chem       Date:  2010-07-07       Impact factor: 5.157

4.  Projection structure of a member of the amino acid/polyamine/organocation transporter superfamily.

Authors:  Fabio Casagrande; Merce Ratera; Andreas D Schenk; Mohamed Chami; Eva Valencia; Jesus Maria Lopez; David Torrents; Andreas Engel; Manuel Palacin; Dimitrios Fotiadis
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

5.  Structural bases for the interaction and stabilization of the human amino acid transporter LAT2 with its ancillary protein 4F2hc.

Authors:  Albert Rosell; Marcel Meury; Elena Álvarez-Marimon; Meritxell Costa; Laura Pérez-Cano; Antonio Zorzano; Juan Fernández-Recio; Manuel Palacín; Dimitrios Fotiadis
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

6.  xCT/SLC7A11 antiporter function inhibits HIV-1 infection.

Authors:  Jesse Rabinowitz; Hamayun J Sharifi; Hunter Martin; Anthony Marchese; Michael Robek; Binshan Shi; Alexander A Mongin; Carlos M C de Noronha
Journal:  Virology       Date:  2021-01-20       Impact factor: 3.616

7.  Primary and secondary thyroid hormone transporters.

Authors:  Anita Kinne; Ralf Schülein; Gerd Krause
Journal:  Thyroid Res       Date:  2011-08-03

Review 8.  The Role of SLC7A11 in Cancer: Friend or Foe?

Authors:  Sijia Li; Zhenyao Lu; Runbin Sun; Suhan Guo; Fangfang Gao; Bei Cao; Jiye Aa
Journal:  Cancers (Basel)       Date:  2022-06-22       Impact factor: 6.575

9.  The ferroptosis inducer erastin irreversibly inhibits system xc- and synergizes with cisplatin to increase cisplatin's cytotoxicity in cancer cells.

Authors:  Mami Sato; Ryosuke Kusumi; Shinji Hamashima; Sho Kobayashi; Satoru Sasaki; Yuhei Komiyama; Takuji Izumikawa; Marcus Conrad; Shiro Bannai; Hideyo Sato
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.